- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05349877
Efficacité d'une intervention brève pour améliorer la santé mentale des minorités sexuelles et de genre : essai contrôlé randomisé. (ESCREVA-SE)
Efficacité d'une brève intervention d'écriture autoguidée en ligne pour améliorer les résultats en matière de santé mentale chez les minorités sexuelles et de genre : un essai contrôlé randomisé.
Experiences of violence, from micro to physical aggressions, have a deleterious impact on mental health. According to the Minority Stress Theory, unfavorable social conditions (such as anticipated and experienced discrimination and internalized homophobia), mediated by resilience strategies, can lead to mental health or illness. Sexual and gender minorities (SGM) face stigma and discrimination aggravating multiple aspects of their lives: from school drop-out to halting health care access. SGM reveal avoiding medical assistance for fear of discrimination while health professionals disclose feeling unprepared to handle SGM health needs. There are two main challenges: 1) developing specific psychological interventions to reduce the impact of stigma and discrimination on SGM' mental health; and 2) training public health professionals to properly address SGM needs. Therefore, the present trial aims to assess the efficacy of a brief, self-guided, on-line, asynchronous and unsupervised psychological intervention in improving SGM' mental health.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90619-900
- Pontifícia Universidade Católica do Rio Grande do Sul
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Self-identity as sexual and gender minority.
- Being older than 16 years old.
- Have a stable on-line connection for, at least, 20 minutes in a place where won't be disturbed.
- Reports, in the baseline survey, previous experiences of discrimination, having depression or anxiety symptoms.
- Currently living in Rio Grande do Sul.
Exclusion Criteria:
- Disagrees with the consent form.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Expressive writing
Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it. |
Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant. |
|
Expérimental: Self-affirmation
Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination. |
Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress. |
|
Comparateur placebo: Placebo
Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week. |
Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline depression at 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Assessed using the Center for Epidemiologic Studies - Depression (CES-D). CES-D is composed of 20 items. The final score ranges from 0 to 60 points. Originally, the cutoff point of the CES-D scale to identify the presence of depressive symptoms is equal or higher 16 points. However, when considering Brazilian samples, the cutoff point of equal or higher 12 points was proposed. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline anxiety at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Evaluated using the Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of 7 questions based in part on the DSM-IV criteria for GAD and reflects the frequency of symptoms during the preceding 2-week period. The GAD-7 requires approximately 1-2 minutes to administer and for each symptom queried provides the following response options: "not at all," "several days," "over half the days" and "nearly every day" and these are scored, respectively, as 0, 1, 2 or 3. A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline social phobia at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Evaluated using the Social Avoidance and Distress Scale (SADS). SADS is a 28 item true/false scale that measures measures aspects of social anxiety including distress, discomfort, fear and avoidance. A total score on the SADS is obtained based on the answers to the true/false questions. Higher scores indicate greater social anxiety. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline post-traumatic stress at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Post-Traumatic Stress Disorder Checklist - Civilian Version (PCL-C). The PCL-C is a 17-item self-report checklist of PTSD symptoms based closely on the DSM-IV criteria. The score consists in adding up all items from each of the 17 items for a total severity score (range = 17-85). The cut off 17-29 shows little to no severity, 28-29 suggests some PTSD symptom, 30-44 moderate to moderately high severity of PTSD symptoms, and 45-85 high severity of PTSD symptoms. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on suicide ideation at 3 and 6 moths after the intervention.
Délai: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a clinically-validated screening tool that healthcare providers use to screen for depression, and also to diagnose and monitor the severity of the condition. A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression. |
Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on substance use at 3 and 6 moths after the intervention.
Délai: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an 8 questions tool that detects substance use and related problems. A 'global continuum of risk score' (or total substance involvement) is calculated by the addition of all items for all substances on the ASSIST and has a maximum score of 208. |
Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on sex risk behaviors at 3 and 6 moths after the intervention.
Délai: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Inquired using yes-no questions concerning unprotected intercourse and multiple sex partners, as well as the Perceived Risk of HIV Scale. Perceived Risk of HIV Scale is a self-report 8-item measure developed to assess how people think and feel about their risk of HIV infection based on their previous sexual behavior and covering several dimensions of perceived HIV risk. Higher scores are associated with a greater number of sex partners, episodes of unprotected sex and having sex while high. |
Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline on resilience at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Wagnild and Youngs's Resilience Scale that has presented the following scoring for the total score: 25-100 = Very low, 101-115 = Low, 116-130 = On the low end, 131-145 = Moderate, 146-160 = Moderately high, and 161-175 = High. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on self-esteem at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Rosenberg Self-Esteem Scale. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles liés aux traumatismes et aux facteurs de stress
- Les troubles mentaux
- Symptômes comportementaux
- Comportement d'automutilation
- Troubles phobiques
- Suicide
- Troubles de stress, traumatiques
- Comportement
- Comportement social
- Comportement sexuel
- Phobie sociale
- Troubles anxieux
- Idéation suicidaire
- La dépression
- Troubles de stress, post-traumatique
- Sexe à risque
- Prise de risque
- Discrimination sociale
Autres numéros d'identification d'étude
- PUCRSBR-10098
- 39059120.0.0000.5336 (Autre identifiant: Brazil's Plataforma Brasil CAAE)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .